GSK Faces U.S. Measles Vaccine Review: New MMR Schedules and Safety StandardsHow GSK navigates US measles‑vaccine scrutiny, exploring new schedules, adjuvants, and safety surveillance to keep the MMR safe and effective.GSK PLC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated Sarah Davidson 09/11/2026, 09:08 4 minutes to read
Vicore Pharma Q3 2026: Strong Cash Position, Rising R&D Losses, and Buloxibutid’s IPF Road‑MapVicore Pharma’s Q3 2026 report shows solid cash, rising R&D spend for buloxibutid, and a clear plan to tackle the $15B IPF market with a potentially differentiated therapy.GSK PLC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated Lisa Martinez 06/11/2026, 18:04 3 minutes to read